EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer

Tara M Hosseini, Sophie S Jang, Joseph Bendik iD, Theresa Guo iD

Cancers · 22.03.2025 · 17 (7) · 1072

DOI: 10.3390/cancers17071072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.03.2025. Verfasst von Tara M Hosseini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, University of California San Diego Altman Clinical and Translational Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: HPV+ head and neck squamous cell carcinoma has been shown to have a unique genomic background, requiring researchers to study it as its own distinct type of cancer. HPV+ tumors have been shown to exhibit fewer genetic mutations in cancer drivers as opposed to their HPV− counterparts. In this paper, we explored how targeting post-transcriptional changes, specifically alternative splicing events, could serve as a potential mechanism to treat HPV+ cancer.

Methods

Using indisulam, a drug that targets alternative splicing through the degradation of RBM39, we treated various HPV+ and HPV− cell lines and assessed tumor cell viability. We also tested indisulam in vivo to evaluate its effect on tumor volume. Additionally, we analyzed gene expression differences between indisulam-treated subjects and their non-treated counterparts.

Results

Indisulam treatment led to a reduction in tumor cell viability in both HPV+ and HPV− cell lines. In vivo experiments showed a reduction in tumor volume following indisulam treatment. Gene expression analysis revealed that indisulam induces consistent differential gene expression changes and highly enriches interferon pathways in treated HPV+ cell lines.

Conclusions

These findings suggest that targeting alternative splicing via indisulam may be a promising therapeutic approach for HPV+ cancers. Further research is required to establish indisulam as a viable anti-cancer treatment in clinical settings.

Schlagwörter

Stichwörter der Autor:innen

HNSCCHPVHPV-negativeHPV-positiveRBM39SCChead and neck squamous cell carcinomaindisulaminterferon-alphainterferon-gamma

Autor:innen und Institutionen

  • Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
  • Department of Otolaryngology-Head & Neck Surgery, University of California San Diego, La Jolla, CA 92093, USA.

ORCID-Profile: Joseph Bendik, Theresa Guo

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • University of California San Diego Altman Clinical and Translational Research Institute
  • National Cancer Institute

Zitieren

APA

Hosseini, T. M., Jang, S. S., Bendik, J., & Guo, T. (2025). Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer. Cancers, 17(7), 1072. https://doi.org/10.3390/cancers17071072

Vancouver

Hosseini TM, Jang SS, Bendik J, Guo T. Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer. Cancers. 2025;17(7):1072. doi:10.3390/cancers17071072

BibTeX
@article{Hosseini2025,
  author = {Hosseini, Tara M and Jang, Sophie S and Bendik, Joseph and Guo, Theresa},
  title = {Indisulam Shows an Anti-Cancer Effect on HPV+ and HPV− Head and Neck Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {1072},
  doi = {10.3390/cancers17071072}
}
Kostenlos starten →